Rempex Pharmaceuticals, Inc.

Qpex Biopharma, Inc.

Metabasis Therapeutics, Inc.

Melinta Subsidiary Corp.

Melinta Therapeutics, Inc.

Raja K Reddy

Scott J Hecker

Maxim Totrov

Serge H Boyer

Olga Rodny

Tomasz W Glinka

Michael N Dudley

David C Griffith

Gavin C Hirst

Venkat Reddy Mali

Qun Dang

Robert Huerta Lemus

Zhili Sun

Haiqing Li

Thanh Huu Nguyen

Matthew P Grote

Jorge E Gomez-Galeno

Paul D Van Poelje

William Craigo

Mingwei Chen

Olga Lomovskaya

Mali Venkat Reddy

Serge Henri Boyer

Paul D Van Polje

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs).

Boronic acid derivatives and therapeutic uses thereof

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.

Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives

Disclosed herein are antimicrobial compounds, compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use a therapeutic agents.

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, &#x3b2;-lactamase inhibitors (BLIs).

The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof and pharmaceutical compositions comprising the same.

Antagonists of the glucagon receptor

Disclosed herein are antimicrobial compounds, compositions, pharmaceutical compositions, and the use and preparation thereof. Some embodiments relate to cyclic boronic acid ester derivatives and their use as therapeutic agents.

Cyclic boronic acid ester derivatives and therapeutic uses thereof

Disclosed herein are antimicrobial compounds having the structure of the formula III' pharmaceutical compositions, the use and preparation thereof. The compounds are of the class of boronic acid derivatives, useful for antimicrobial treatment.

Substituted boronic acids as antimicrobials

The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.

Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.

Growing community of inventors

San Diego, CA, United States of America

Raja K Reddy